Introduction: Androgen deprivation therapy (ADT) with androgen receptor axis-targeted (ARAT) is the standard of care provided to patients metastatic prostate cancer. While effective, it results in sequelae, such as loss skeletal muscle mass. In this study, we compared sarcopenic effects abiraterone and enzalutamide, two ARATs used treat Methods: Our cohort comprised 55 diagnosed hormone-naive c...

Aim : to examine an efficacy of various stimulation methods in a group successful pregnancies. Materials and Methods . In single center retrospective study 47 pregnancy cases were examined after performing embryo transfers at our institution from the years 2017 2021. Patients divided into four groups: i) clomiphene hyperstimulation (CH), ii) with gonadotropin-releasing hormone (GnRH) agonist, i...

Apparently, no agonist has been found that is comparable in potency to the luteinizing hormone-releasing hormone (LHRH) for release of LH and follicle-stimulating hormone (FSH) without substitutions with unnatural or D forms of natural amino acids. Of 139 known "agonist analogs" of LHRH, two were active in the range of 65%. The four LHRHs known to occur in nature involve a total of six amino ac...

Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a |n-1 rp"| agonist of luteinizing hormone releasing hormone (LH-RH), somatostatin analogue (RC-160), and bombesin/gastrin releasing peptide antagonist (RC-309S). Some inhibitory effect of [D-Trp'| LH-RH microcapsules releasing 25 fig/day on tumor growth was observed that could be due to sex steroid...

Men with prostate cancer may be at increased risk for metabolic syndrome, cardiovascular disease, and diabetes from androgen deprivation therapy (ADT). This article reviews current literature related to potential adverse effects of using ADT for localized prostate cancer. The use of gonadotropin-releasing hormone agonist therapy for prostate cancer in the early 1990s compared to the late 1990s ...

Prolonged juvenile hypothyroidism results in a permanent loss in height that is related to the duration of thyroxine deficiency before adequate thyroxine replacement treatment. A 13 year old girl with severe juvenile hypothyroidism was studied prospectively. She had an undetectable serum thyroxine concentration, a height SD score of -6.6 SD, and a bone age of 5.8 years. The enlarged pituitary g...

Nine normal volunteers and 15 patients with pituitary disorders were given a combined test of anterior pituitary function using four hypothalamic releasing factors and arginine vasopressin. Rapid sequential intravenous infusions of human corticotrophin releasing factor 100 micrograms, growth hormone releasing factor 100 micrograms, luteinising hormone releasing hormone 100 micrograms, and thyro...

Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, o...

Men with advanced or metastatic prostate cancer commonly receive long-term treatment with luteinizing hormone-releasing hormone (LHRH) agonist therapy. This prolonged treatment causes a hypogonadal state of chronic testosterone deficiency. Similar to estrogen deficiency in postmenopausal women, testosterone deficiency among these men negatively affects bone metabolism through a complex self-reg...

Tamoxifen treatment for breast cancer may induce ovarian cysts and supraphysiological levels of serum estrogen. We report successful management with luteinizing hormone-releasing hormone (LHRH) agonist of ovarian hyperstimulation induced by tamoxifen. A 49-year-old woman was operated on for invasive ductal carcinoma of the right breast. She received breast irradiation and adjuvant tamoxifen the...